PARP1 and colorectal carcinoma: Notably, the PARP inhibitor niraparib, combined with IR, produces excessive cytoplasmic double-stranded DNA in CRC, which is sensed by cGAS, thereby eliciting a cGAS-mediated antitumour immune response through the increased infiltration and activation of cytotoxic CD8 + T cells [144].